249 related articles for article (PubMed ID: 36404302)
21. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity.
To KK; Lo WU; Chan JF; Tse H; Cheng VC; Ho PL
Int J Infect Dis; 2013 Feb; 17(2):e120-4. PubMed ID: 23098812
[TBL] [Abstract][Full Text] [Related]
22. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
[TBL] [Abstract][Full Text] [Related]
23. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.
Joo EJ; Park DA; Lee NR; Moon SY; Choi JK; Ko JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2093-2100. PubMed ID: 28643188
[TBL] [Abstract][Full Text] [Related]
24. No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia.
Heng ST; Chen SL; Wong JGX; Lye DC; Ng TM
Sci Rep; 2018 Aug; 8(1):12785. PubMed ID: 30143706
[TBL] [Abstract][Full Text] [Related]
25. Do Weekly Surveillance Cultures Contribute to Antibiotic Stewardship and Correlate with Outcome of HSCT in Children? A Multicenter Real-World Experience of 5 Years from the Indian Subcontinent.
Dhanya R; Agarwal RK; Ramprakash S; Trivedi D; Shah V; Bhat N; Reddy M; Elizabeth S; Batool A; Khalid S; Faulkner L
Transplant Cell Ther; 2022 Mar; 28(3):170.e1-170.e7. PubMed ID: 34936930
[TBL] [Abstract][Full Text] [Related]
26. Sepsis Caused by Extended-Spectrum Beta-Lactamase (ESBL)-Positive K. pneumoniae and E. coli: Comparison of Severity of Sepsis, Delay of Anti-Infective Therapy and ESBL Genotype.
Sakellariou C; Gürntke S; Steinmetz I; Kohler C; Pfeifer Y; Gastmeier P; Schwab F; Kola A; Deja M; Leistner R
PLoS One; 2016; 11(7):e0158039. PubMed ID: 27442425
[TBL] [Abstract][Full Text] [Related]
27. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Antimicrob Agents Chemother; 2012 Jun; 56(6):2888-93. PubMed ID: 22430969
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
Haruki Y; Hagiya H; Haruki M; Sugiyama T
J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
[TBL] [Abstract][Full Text] [Related]
29. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis.
Yang CC; Li SH; Chuang FR; Chen CH; Lee CH; Chen JB; Wu CH; Lee CT
BMC Infect Dis; 2012 Sep; 12():206. PubMed ID: 22947300
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
Kiremitci A; Dinleyici EC; Erben N; Durmaz G; Yargic ZA; Aybey AD; Usluer G
Expert Opin Pharmacother; 2008 Jun; 9(9):1441-9. PubMed ID: 18518776
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia.
Ku NS; Kim YC; Kim MH; Song JE; Oh DH; Ahn JY; Kim SB; Kim HW; Jeong SJ; Han SH; Kim CO; Song YG; Kim JM; Choi JY
Arch Gerontol Geriatr; 2014; 58(1):105-9. PubMed ID: 23988261
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and patient related factors associated with Extended-Spectrum Beta-Lactamase producing Escherichia coli and Klebsiella pneumoniae carriage and infection among pediatric patients in Tanzania.
Letara N; Ngocho JS; Karami N; Msuya SE; Nyombi B; Kassam NA; Skovbjerg S; Åhren C; Philemon R; Mmbaga BT
Sci Rep; 2021 Nov; 11(1):22759. PubMed ID: 34815472
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
Park SH; Choi SM; Chang YK; Lee DG; Cho SY; Lee HJ; Choi JH; Yoo JH
J Antimicrob Chemother; 2014 Oct; 69(10):2848-56. PubMed ID: 24928854
[TBL] [Abstract][Full Text] [Related]
34. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
35. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
[TBL] [Abstract][Full Text] [Related]
36. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae.
Katip W; Yoodee J; Uitrakul S; Oberdorfer P
Sci Rep; 2021 Jan; 11(1):18. PubMed ID: 33420122
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae.
Lee JA; Kang CI; Joo EJ; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Ko KS; Lee NY; Song JH
Microb Drug Resist; 2011 Jun; 17(2):267-73. PubMed ID: 21388296
[TBL] [Abstract][Full Text] [Related]
39. Mortality risk of bloodstream infection caused by either Escherichia coli or Klebsiella pneumoniae producing extended-spectrum β-lactamase: a prospective cohort study.
Sianipar O; Asmara W; Dwiprahasto I; Mulyono B
BMC Res Notes; 2019 Nov; 12(1):719. PubMed ID: 31675991
[TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
